Baidu
map

CHEST:言语治疗和普瑞巴林联合治疗慢性顽固性咳嗽更优

2016-03-09 崔倩 译 MedSci原创

慢性难治咳嗽(CRC)是一种难以治疗的问题。言语病理学治疗(SPT)可以改善症状,但缓解率是不完整的。作用于中枢的神经调节也可以改善咳嗽的症状,但咳嗽反射不敏感,效果是短暂的。研究人员假设,联合SPT和作用于中枢的神经调节会比单独SPT治疗结果会更好。该研究的目标是确定是否普瑞巴林和SPT联合治疗比单独SPT更有效。这是一项随机,安慰剂对照试验。40例结直肠癌患者随机分配接受联合SPT和普瑞巴林每

慢性顽固性咳嗽(CRC)是一种难以治愈的疾病。言语治疗(SPT)可以改善症状,但缓解率是不完整的。作用于中枢的神经调节也可以改善咳嗽的症状,但咳嗽反射不敏感,效果是短暂的。研究人员假设,联合SPT和作用于中枢的神经调节会比单独SPT治疗结果会更好。该研究的目标是确定是否普瑞巴林和SPT联合治疗比单独SPT更有效。

这是一项随机,安慰剂对照试验。40例结直肠癌患者随机分配接受联合SPT和普瑞巴林每天300mg或SPT和安慰剂结合治疗。主要结果指标在基线,治疗结束,和治疗结束后4周进行收集。主要成果是莱斯特咳嗽监测的咳嗽频率,采用莱斯特咳嗽问卷(LCQ),咳嗽的严重程度采用视觉模拟量表(coughVAS)评估,采用莱斯特咳嗽问卷(LCQ)评估的与咳嗽有关的生活质量(QOL)。

两组的咳嗽严重程度,咳嗽频率和咳嗽生活质量都有所改善。SPT和普瑞巴林联合治疗组的LCQ和coughVAS改善程度都比单独SPT治疗要大;LCQ的平均差异为3.5,95%CI为1.1-5.8;coughVAS的平均差异为25.1,95%CI为10.6—39.6。两组间咳嗽频率的改善无显著差异。普瑞巴林被撤回时症状没有恶化。联合SPT和普瑞巴林治疗组的平均辣椒素咳嗽敏感性从15.7提高到47.5μM,而单独SPT治疗从3.92提高到15.7μM。

在CRC患者中,与单独SPT治疗相比,SPT和普瑞巴林联合治疗可减少症状并提高生活质量。

原始出处:

Anne E. Vertigan,Sarah L. Kapela,Nicole M. Ryan,et al.Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough.CHEST.2016.3.8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929243, encodeId=6e3519292435c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 16 08:21:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632857, encodeId=96cb163285ebc, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Jul 21 18:21:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050536, encodeId=23772050536d6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310294, encodeId=529e131029462, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=)]
    2016-12-16 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929243, encodeId=6e3519292435c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 16 08:21:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632857, encodeId=96cb163285ebc, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Jul 21 18:21:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050536, encodeId=23772050536d6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310294, encodeId=529e131029462, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929243, encodeId=6e3519292435c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 16 08:21:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632857, encodeId=96cb163285ebc, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Jul 21 18:21:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050536, encodeId=23772050536d6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310294, encodeId=529e131029462, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929243, encodeId=6e3519292435c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 16 08:21:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632857, encodeId=96cb163285ebc, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Jul 21 18:21:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050536, encodeId=23772050536d6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310294, encodeId=529e131029462, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929243, encodeId=6e3519292435c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri Dec 16 08:21:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632857, encodeId=96cb163285ebc, content=<a href='/topic/show?id=5e1110013180' target=_blank style='color:#2F92EE;'>#顽固性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100131, encryptionId=5e1110013180, topicName=顽固性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4121955726, createdName=limedical1981, createdTime=Thu Jul 21 18:21:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050536, encodeId=23772050536d6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310294, encodeId=529e131029462, content=<a href='/topic/show?id=24795994515' target=_blank style='color:#2F92EE;'>#普瑞巴林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59945, encryptionId=24795994515, topicName=普瑞巴林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313646, encodeId=ac271313646ea, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Fri Mar 11 08:21:00 CST 2016, time=2016-03-11, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map